Goldman Sachs warned there's a risk of a 5% slump in US stocks because ... retreated after President Trump imposed an additional 10% tariff on Chinese goods. Moderna (MRNA) closed down more than -7% ...

Barclays downgraded shares of Moderna (NASDAQ:MRNA – Free Report) from an overweight rating to an equal weight rating in a report published on Tuesday, Ratings reports. The firm currently has $45.00 ...

China is starting to see a rebound in M&As as government stimulus measures start to bear fruit and pressure from Donald Trump ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

CSL and Cochlear are two of Australia’s blue-chip healthcare stocks, stalwarts of many investors portfolios, whereas Pro ...

Investors seeking to outperform the market should focus their stock-picking efforts on volatile names in the consumer ...

Moderna is now expecting 2025 research and development costs of about $4.1 billion and selling, general and administrative costs of about $1.1 billion. Cost of sales is expected to come to about $1.2 ...

The Dow Jones Industrial Average shed 165.35 points, or 0.37%, closing at 44,546.08. The S&P 500 ticked down 0.01% to ...

Shares of Roku Inc (NASDAQ:ROKU) are up 14.5% in premarket trading, after the streaming giant shared smaller-than-expected losses for the fourth quarter as well as a revenue beat. The company also ...

Moderna (NASDAQ:MRNA – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Friday, February 14th. Analysts expect the company to announce earnings of ($2.

Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...

Giovanni left Goldman Sachs in 2021 to become chief financial officer at the online grocery delivery company, a former client. He ended his time with Instacart in June. On Tuesday, he announced ...